# Elda Tagliabue

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2335679/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 205 papers | 10,954 citations | 31976 53 h-index | 37204 96 g-index |
| 211 all docs | 211 docs citations | 211 times ranked | 14410 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2. Clinical Cancer Research, 2004, 10, 5650-5655. | 7.0 | 470 |
| 2 | Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation. Seminars in Cancer Biology, 2017, 43, 74-89. | 9.6 | 414 |
| 3 | Potential role of HER2â€overexpressing exosomes in countering trastuzumabâ€based therapy. Journal of Cellular Physiology, 2012, 227, 658-667. | 4.1 | 410 |
| 4 | Biologic and therapeutic role of HER2 in cancer. Oncogene, 2003, 22, 6570-6578. | 5.9 | 379 |
| 5 | microRNA-205 Regulates HER3 in Human Breast Cancer. Cancer Research, 2009, 69, 2195-2200. | 0.9 | 334 |
| 6 | Replacement of Fhit in cancer cells suppressesâ€‰tumorigenicity. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 13771-13776. | 7.1 | 333 |
| 7 | Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. Journal of Pathology, 2008, 214, 357-367. | 4.5 | 311 |
| 8 | Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. International Journal of Cancer, 1987, 39, 297-303. | 5.1 | 284 |
| 9 | New insights into the role of extracellular matrix during tumor onset and progression. Journal of Cellular Physiology, 2002, 192, 259-267. | 4.1 | 279 |
| 10 | FOXP3 Expression and Overall Survival in Breast Cancer. Journal of Clinical Oncology, 2009, 27, 1746-1752. | 1.6 | 271 |
| 11 | Role of HER2 gene overexpression in breast carcinoma. Journal of Cellular Physiology, 2000, 182, 150-162. | 4.1 | 258 |
| 12 | Tripleâ€negative breast cancer: Present challenges and new perspectives. Molecular Oncology, 2010, 4, 209-229. | 4.6 | 252 |
| 13 | Tumor-Initiating Cells of HER2-Positive Carcinoma Cell Lines Express the Highest Oncoprotein Levels and Are Sensitive to Trastuzumab. Clinical Cancer Research, 2009, 15, 2010-2021. | 7.0 | 238 |
| 14 | Elements Related to Heterogeneity of Antibody-Dependent Cell Cytotoxicity in Patients Under Trastuzumab Therapy for Primary Operable Breast Cancer Overexpressing Her2. Cancer Research, 2007, 67, 11991-11999. | 0.9 | 210 |
| 15 | Role of HER2 in wound-induced breast carcinoma proliferation. Lancet, The, 2003, 362, 527-533. | 13.7 | 152 |
| 16 | Oncosuppressive role of p53â€induced miRâ€205 in triple negative breast cancer. Molecular Oncology, 2012, 6, 458-472. | 4.6 | 142 |
| 17 | Modulation of Pulmonary Microbiota by Antibiotic or Probiotic Aerosol Therapy: A Strategy to Promote Immunosurveillance against Lung Metastases. Cell Reports, 2018, 24, 3528-3538. | 6.4 | 141 |
| 18 | The 67 kDa laminin receptor as a prognostic factor in human cancer. Breast Cancer Research and Treatment, 1998, 52, 137-145. | 2.5 | 139 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. European Journal of Cancer, 2008, 44, 2753-2759. | 2.8 | 138 |
| 20 | WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer. Oncogene, 2019, 38, 4047-4060. | 5.9 | 137 |
| 21 | Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers. Cancer Letters, 2017, 384, 94-100. | 7.2 | 131 |
| 22 | Prognostic Significance of the 67-Kilodalton Laminin Receptor Expression in Human Breast Carcinomas. Journal of the National Cancer Institute, 1993, 85, 398-402. | 6.3 | 130 |
| 23 | Oncogenic protein tyrosine kinases. Cellular and Molecular Life Sciences, 2004, 61, 2965-2978. | 5.4 | 125 |
| 24 | New insights into the metastasis-associated 67 kD laminin receptor. Journal of Cellular Biochemistry, 1997, 67, 155-165. | 2.6 | 121 |
| 25 | Tumor-extracellular matrix interactions: Identification of tools associated with breast cancer progression. Seminars in Cancer Biology, 2015, 35, 3-10. | 9.6 | 120 |
| 26 | Role of exon-16-deleted HER2 in breast carcinomas. Endocrine-Related Cancer, 2006, 13, 221-232. | 3.1 | 112 |
| 27 | Formation of the 67-kDa laminin receptor by acylation of the precursor. Journal of Cellular Biochemistry, 1998, 69, 244-251. | 2.6 | 104 |
| 28 | The lung microbiota: role in maintaining pulmonary immune homeostasis and its implications in cancer development and therapy. Cellular and Molecular Life Sciences, 2020, 77, 2739-2749. | 5.4 | 103 |
| 29 | Selection of monoclonal antibodies which induce internalization and phosphorylation of P185HER2 and growth inhibition of cells with HER2/neu gene amplification. International Journal of Cancer, 1991, 47, 933-937. | 5.1 | 99 |
| 30 | Exploiting poly(I:C) to induce cancer cell apoptosis. Cancer Biology and Therapy, 2017, 18, 747-756. | 3.4 | 92 |
| 31 | Breast cancer and microRNAs: therapeutic impact. Breast, 2011, 20, S63-S70. | 2.2 | 87 |
| 32 | FOXP3 expression in tumor cells and implications for cancer progression. Journal of Cellular Physiology, 2013, 228, 30-35. | 4.1 | 87 |
| 33 | Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity. Cell Reports, 2016, 17, 233-248. | 6.4 | 84 |
| 34 | HER2 as a target for breast cancer therapy. Expert Opinion on Biological Therapy, 2010, 10, 711-724. | 3.1 | 78 |
| 35 | Co-regulation and Physical Association of the 67-kDa Monomeric Laminin Receptor and the Î±6Î²4 Integrin. Journal of Biological Chemistry, 1997, 272, 2342-2345. | 3.4 | 77 |
| 36 | Expression of protein tyrosine phosphatase alpha (RPTPÎ±) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo. Oncogene, 2000, 19, 4979-4987. | 5.9 | 77 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Human ovarian carcinoma lysis by cytotoxic t cells targeted by bispecific monoclonal antibodies: Analysis of the antibody components. International Journal of Cancer, 1988, 41, 609-615. | 5.1 | 70 |
| 38 | The Human Splice Variant Î”16HER2 Induces Rapid Tumor Onset in a Reporter Transgenic Mouse. PLoS ONE, 2011, 6, e18727. | 2.5 | 70 |
| 39 | miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response. Oncotarget, 2016, 7, 786-797. | 1.8 | 70 |
| 40 | Expression of Bone Sialoprotein in Human Lung Cancer. Calcified Tissue International, 1997, 61, 183-188. | 3.1 | 69 |
| 41 | The 67 kDa laminin receptor increases tumor aggressiveness by remodeling laminin-1. Endocrine-Related Cancer, 2005, 12, 393-406. | 3.1 | 69 |
| 42 | Tumor Extracellular Matrix Remodeling: New Perspectives as a Circulating Tool in the Diagnosis and Prognosis of Solid Tumors. Cells, 2019, 8, 81. | 4.1 | 69 |
| 43 | Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: A randomized clinical trial (INT09/98). Cancer, 2014, 120, 885-893. | 4.1 | 68 |
| 44 | Salad vegetables dietary pattern protects against HER-2-positive breast cancer: A prospective Italian study. International Journal of Cancer, 2007, 121, 911-914. | 5.1 | 65 |
| 45 | Radiation Effects on Development of HER2-Positive Breast Carcinomas. Clinical Cancer Research, 2007, 13, 46-51. | 7.0 | 64 |
| 46 | Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab. Cancer Research, 2014, 74, 6248-6259. | 0.9 | 63 |
| 47 | Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer. Cancer Research, 2021, 81, 2195-2206. | 0.9 | 63 |
| 48 | International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). Journal of the National Cancer Institute Monographs, 2011, 2011, 147-151. | 2.1 | 61 |
| 49 | Identification of a novel function for 67-kDa laminin receptor: increase in laminin degradation rate and release of motility fragments. Cancer Research, 2002, 62, 1321-5. | 0.9 | 60 |
| 50 | Regulation of Breast Cancer Response to Chemotherapy by Fibulin-1. Cancer Research, 2007, 67, 4271-4277. | 0.9 | 59 |
| 51 | HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clinical Cancer Research, 2002, 8, 520-5. | 7.0 | 58 |
| 52 | Nerve Growth Factor Cooperates with p185 in Activating Growth of Human Breast Carcinoma Cells. Journal of Biological Chemistry, 2000, 275, 5388-5394. | 3.4 | 57 |
| 53 | HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy. OncoImmunology, 2019, 8, e1512942. | 4.6 | 57 |
| 54 | Induction of Paneth cell degranulation by orally administered Tollâ€like receptor ligands. Journal of Cellular Physiology, 2012, 227, 1107-1113. | 4.1 | 56 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. BMC Cancer, 2010, 10, 378. | 2.6 | 55 |
| 56 | Characterization of two monoclonal antibodies directed against the 67 kDa high affinity laminin receptor and application for the study of breast carcinoma progression. Clinical and Experimental Metastasis, 1992, 10, 379-386. | 3.3 | 54 |
| 57 | Adipocytes in Breast Cancer, the Thick and the Thin. Cells, 2020, 9, 560. | 4.1 | 54 |
| 58 | Immunodetection of bone marrow micrometastases in breast carcinoma patients and its correlation with primary tumour prognostic features. British Journal of Cancer, 1994, 69, 1126-1129. | 6.4 | 52 |
| 59 | Extracellular matrix proteins as diagnostic markers of breast carcinoma. Journal of Cellular Physiology, 2018, 233, 6280-6290. | 4.1 | 49 |
| 60 | Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors. Cellular Oncology, 2010, 32, 361-72. | 1.9 | 48 |
| 61 | Diagnostic role of circulating extracellular matrix-related proteins in non-small cell lung cancer. BMC Cancer, 2018, 18, 899. | 2.6 | 45 |
| 62 | Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (donâ€™t) know. Journal of Experimental and Clinical Cancer Research, 2020, 39, 236. | 8.6 | 44 |
| 63 | Influence of Antibiotic Treatment on Breast Carcinoma Development in Proto-neu Transgenic Mice. Cancer Research, 2006, 66, 6219-6224. | 0.9 | 43 |
| 64 | Neoplastic and Stromal Cells Contribute to an Extracellular Matrix Gene Expression Profile Defining a Breast Cancer Subtype Likely to Progress. PLoS ONE, 2013, 8, e56761. | 2.5 | 41 |
| 65 | Cancer-Associated Adipocytes in Breast Cancer: Causes and Consequences. International Journal of Molecular Sciences, 2021, 22, 3775. | 4.1 | 41 |
| 66 | Antibiotic-induced disturbances of the gut microbiota result in accelerated breast tumor growth. IScience, 2021, 24, 103012. | 4.1 | 41 |
| 67 | Decoding Immune Heterogeneity of Triple Negative Breast Cancer and Its Association with Systemic Inflammation. Cancers, 2019, 11, 911. | 3.7 | 40 |
| 68 | Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition. Oncotarget, 2016, 7, 255-265. | 1.8 | 39 |
| 69 | Ricin A Chain Conjugated With Monoclonal Antibodies Selectively Killing Human Carcinoma Cells In Vitro2. Journal of the National Cancer Institute, 1985, 75, 831-839. | 6.3 | 38 |
| 70 | Peptide G, Containing the Binding Site of the 67-kDa Laminin Receptor, Increases and Stabilizes Laminin Binding to Cancer Cells. Journal of Biological Chemistry, 1996, 271, 31179-31184. | 3.4 | 38 |
| 71 | TLR9 Agonists Oppositely Modulate DNA Repair Genes in Tumor versus Immune Cells and Enhance Chemotherapy Effects. Cancer Research, 2011, 71, 6382-6390. | 0.9 | 37 |
| 72 | PDGFRÎ² and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells. Molecular Oncology, 2014, 8, 968-981. | 4.6 | 37 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment. OncoImmunology, 2015, 4, e1040214. | 4.6 | 37 |
| 74 | TLR3 Expression Induces Apoptosis in Human Non-Small-Cell Lung Cancer. International Journal of Molecular Sciences, 2020, 21, 1440. | 4.1 | 37 |
| 75 | Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer. Oncogene, 2017, 36, 1721-1732. | 5.9 | 36 |
| 76 | FHIT-proteasome degradation caused by mitogenic stimulation of the EGF receptor family in cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18981-18986. | 7.1 | 35 |
| 77 | Association of adiposity, dysmetabolisms, and inflammation with aggressive breast cancer subtypes: a cross-sectional study. Breast Cancer Research and Treatment, 2016, 157, 179-189. | 2.5 | 34 |
| 78 | Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration. Oncotarget, 2015, 6, 28173-28182. | 1.8 | 34 |
| 79 | Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit. British Journal of Cancer, 2018, 119, 1487-1494. | 6.4 | 33 |
| 80 | Sensitivity Enhancement of the Cytologic Detection of Cancer Cells in Effusions by Monoclonal Antibodies. American Journal of Clinical Pathology, 1985, 83, 571-576. | 0.7 | 31 |
| 81 | p53-dependent downregulation of metastasis-associated laminin receptor. Oncogene, 2002, 21, 7478-7487. | 5.9 | 31 |
| 82 | Activity and resistance of trastuzumab according to different clinical settings. Cancer Treatment Reviews, 2012, 38, 212-217. | 7.7 | 31 |
| 83 | Molecular portrait of breast cancer in <scp>C</scp>hina reveals comprehensive transcriptomic likeness to <scp>C</scp>aucasian breast cancer and low prevalence of luminal A subtype. Cancer Medicine, 2015, 4, 1016-1030. | 2.8 | 31 |
| 84 | Intratumor lactate levels reflect HER2 addiction status in HER2â€positive breast cancer. Journal of Cellular Physiology, 2019, 234, 1768-1779. | 4.1 | 31 |
| 85 | Prognostic significance of laminin production in relation with its receptor expression in human breast carcinomas. Breast Cancer Research and Treatment, 1995, 35, 195-199. | 2.5 | 30 |
| 86 | HER-2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine. Journal of Cellular Physiology, 2005, 205, 10-18. | 4.1 | 30 |
| 87 | Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. Annals of Oncology, 2008, 19, 1706-1712. | 1.2 | 30 |
| 88 | Reprogramming the lung microenvironment by inhaled immunotherapy fosters immune destruction of tumor. OncoImmunology, 2016, 5, e1234571. | 4.6 | 30 |
| 89 | p185 HER2/neu Epitope Mapping with Murine Monoclonal Antibodies. Hybridoma, 1992, 11, 267-276. | 0.6 | 29 |
| 90 | Protein Kinase CÎ± Determines HER2 Fate in Breast Carcinoma Cells with HER2 Protein Overexpression without Gene Amplification. Cancer Research, 2007, 67, 5308-5317. | 0.9 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers. Oncotarget, 2016, 7, 69649-69665. | 1.8 | 29 |
| 92 | Expression of long nonâ€coding <scp>RNA ENSG</scp>00000226738 (Lnc<scp>KLHDC</scp>7B) is enriched in the immunomodulatory tripleâ€negative breast cancer subtype and its alteration promotes cell migration, invasion, and resistance to cell death. Molecular Oncology, 2019, 13, 909-927. | 4.6 | 29 |
| 93 | Improvement of Tumor Cell Detection Using a Pool of Monoclonal Antibodies. Hybridoma, 1986, 5, 107-115. | 0.6 | 28 |
| 94 | Shed HER2 extracellular domain in HER2â€mediated tumor growth and in trastuzumab susceptibility. Journal of Cellular Physiology, 2010, 225, 256-265. | 4.1 | 28 |
| 95 | Infiltrating Mast Cellâ€“Mediated Stimulation of Estrogen Receptor Activity in Breast Cancer Cells Promotes the Luminal Phenotype. Cancer Research, 2020, 80, 2311-2324. | 0.9 | 28 |
| 96 | Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. Annals of Oncology, 2007, 18, 601-602. | 1.2 | 26 |
| 97 | Ascites Regression and Survival Increase in Mice Bearing Advanced-stage Human Ovarian Carcinomas and Repeatedly Treated Intraperitoneally With CpG-ODN. Journal of Immunotherapy, 2010, 33, 8-15. | 2.4 | 26 |
| 98 | Cancer Stem Cells: Devil or Saviorâ€”Looking behind the Scenes of Immunotherapy Failure. Cells, 2020, 9, 555. | 4.1 | 26 |
| 99 | Genetic changes in lung cancer. Journal of Cellular Biochemistry, 1993, 53, 237-248. | 2.6 | 25 |
| 100 | Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study. Breast Cancer Research and Treatment, 2013, 141, 101-110. | 2.5 | 25 |
| 101 | Secondary electrospray ionization-mass spectrometry and a novel statistical bioinformatic approach identifies a cancer-related profile in exhaled breath of breast cancer patients: a pilot study. Journal of Breath Research, 2015, 9, 031001. | 3.0 | 25 |
| 102 | Activation of NK cell cytotoxicity by aerosolized CpG-ODN/poly(I:C) against lung melanoma metastases is mediated by alveolar macrophages. Cellular Immunology, 2017, 313, 52-58. | 3.0 | 25 |
| 103 | Fluctuation of HER2 Expression in Breast Carcinomas during the Menstrual Cycle. American Journal of Pathology, 1999, 155, 1543-1547. | 3.8 | 24 |
| 104 | Evaluation of arrayed primer extension for TP53 mutation detection in breast and ovarian carcinomas. BioTechniques, 2005, 39, 755-761. | 1.8 | 24 |
| 105 | Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients. Annals of Oncology, 2011, 22, 1886-1893. | 1.2 | 24 |
| 106 | EGFR through STAT3 modulates Î”N63Î± expression to sustain tumorâ€initiating cell proliferation in squamous cell carcinomas. Journal of Cellular Physiology, 2013, 228, 871-878. | 4.1 | 24 |
| 107 | Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge. Future Oncology, 2016, 12, 1413-1428. | 2.4 | 24 |
| 108 | Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host. Disease Markers, 2017, 2017, 1-14. | 1.3 | 24 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. Breast Cancer Research and Treatment, 2011, 128, 147-154. | 2.5 | 23 |
| 110 | Quantification of Circulating Cancer Biomarkers via Sensitive Topographic Measurements on Single Binder Nanoarrays. ACS Omega, 2017, 2, 2618-2629. | 3.5 | 23 |
| 111 | Characterization of a monoclonal antibody directed against the epidermal growth factor receptor binding site. Cancer Immunology, Immunotherapy, 1991, 34, 37-42. | 4.2 | 22 |
| 112 | Shedding of the 67-kD laminin receptor by human cancer cells. , 1996, 60, 226-234. | | 22 |
| 113 | The landscape of d16HER2 splice variant expression across HER2-positive cancers. Scientific Reports, 2019, 9, 3545. | 3.3 | 22 |
| 114 | Production and Characterization of two Monoclonal Antibodies Directed against the Integrin Î²<sub>1</sub>Chain. Tumori, 1992, 78, 1-4. | 1.1 | 21 |
| 115 | The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?. Cancers, 2019, 11, 902. | 3.7 | 21 |
| 116 | Increased Sensitivity to Chemotherapy Induced by CpG-ODN Treatment Is Mediated by microRNA Modulation. PLoS ONE, 2013, 8, e58849. | 2.5 | 21 |
| 117 | Two Distinct Local Relapse Subtypes in Invasive Breast Cancer: Effect on their Prognostic Impact. Clinical Cancer Research, 2008, 14, 25-31. | 7.0 | 20 |
| 118 | Antiâ€tumor activity of CpGâ€ODN aerosol in mouse lung metastases. International Journal of Cancer, 2013, 133, 383-393. | 5.1 | 20 |
| 119 | Breast Cancer Drug Resistance: Overcoming the Challenge by Capitalizing on MicroRNA and Tumor Microenvironment Interplay. Cancers, 2021, 13, 3691. | 3.7 | 20 |
| 120 | Heregulin Î²1 induces the down regulation and the ubiquitin-proteasome degradation pathway of p185HER2oncoprotein. FEBS Letters, 1998, 422, 129-131. | 2.8 | 19 |
| 121 | Diadenosines as FHIT-ness instructors. Journal of Cellular Physiology, 2006, 208, 274-281. | 4.1 | 19 |
| 122 | Fhit Expression Protects Against HER2-Driven Breast tumor Development: Unraveling the Molecular Interconnections. Cell Cycle, 2007, 6, 643-646. | 2.6 | 19 |
| 123 | ECM Remodeling in Breast Cancer with Different Grade: Contribution of 2Dâ€DIGE Proteomics. Proteomics, 2018, 18, e1800278. | 2.2 | 19 |
| 124 | Wound Healing Fluid Reflects the Inflammatory Nature and Aggressiveness of Breast Tumors. Cells, 2019, 8, 181. | 4.1 | 19 |
| 125 | HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response. Oncotarget, 2017, 8, 54444-54458. | 1.8 | 19 |
| 126 | Do Pre-Diagnostic Drinking Habits Influence Breast Cancer Survival?. Tumori, 2011, 97, 142-148. | 1.1 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | High efficacy of CpG-ODN, Cetuximab and Cisplatin combination for very advanced ovarian xenograft tumors. Journal of Translational Medicine, 2013, 11, 25. | 4.4 | 18 |
| 128 | Pleiotropic antitumor effects of the panâ€HDAC inhibitor ITF2357 against câ€Mycâ€overexpressing human Bâ€cell nonâ€Hodgkin lymphomas. International Journal of Cancer, 2014, 135, 2034-2045. | 5.1 | 18 |
| 129 | Toll Like Receptors as Sensors of the Tumor Microbial Dysbiosis: Implications in Cancer Progression. Frontiers in Cell and Developmental Biology, 2021, 9, 732192. | 3.7 | 18 |
| 130 | Aerosol Delivery in the Treatment of Lung Cancer. Current Cancer Drug Targets, 2015, 15, 604-612. | 1.6 | 18 |
| 131 | CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts. Journal of Translational Medicine, 2016, 14, 25. | 4.4 | 17 |
| 132 | Toll-like receptor 3 as a new marker to detect high risk early stage Non-Small-Cell Lung Cancer patients. Scientific Reports, 2019, 9, 14288. | 3.3 | 17 |
| 133 | Human carcinoma cell lines xenografted in athymic mice: biological and antigenic characteristics of an intraabdominal model. Cancer Immunology, Immunotherapy, 1987, 24, 13-8. | 4.2 | 16 |
| 134 | Colocalization of the p185HER2 oncoprotein and integrin Î±6Î²4 in Calu-3 lung carcinoma cells. Journal of Cellular Biochemistry, 1994, 55, 409-418. | 2.6 | 16 |
| 135 | Relationship between p53 and p27 expression following HER2 signaling. Breast, 2007, 16, 597-605. | 2.2 | 16 |
| 136 | Antitumor Efficacy of Trastuzumab in Nude Mice Orthotopically Xenografted With Human Pancreatic Tumor Cells Expressing Low Levels of HER-2/neu. Journal of Immunotherapy, 2008, 31, 537-544. | 2.4 | 16 |
| 137 | Expression and prognostic significance of the autoimmune regulator gene in breast cancer cells. Cell Cycle, 2016, 15, 3220-3229. | 2.6 | 16 |
| 138 | The PDGFRÎ²/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer. BMC Cancer, 2018, 18, 586. | 2.6 | 16 |
| 139 | Inhibition of the Wnt Signalling Pathway: An Avenue to Control Breast Cancer Aggressiveness. International Journal of Molecular Sciences, 2020, 21, 9069. | 4.1 | 16 |
| 140 | Do pre-diagnostic drinking habits influence breast cancer survival?. Tumori, 2011, 97, 142-8. | 1.1 | 16 |
| 141 | Monoclonal antibodies against doxorubicin. International Journal of Cancer, 1988, 42, 798-802. | 5.1 | 15 |
| 142 | cIAP1 regulates the EGFR/Snai2 axis in triple-negative breast cancer cells. Cell Death and Differentiation, 2018, 25, 2147-2164. | 11.2 | 15 |
| 143 | Local Administration of Caloric Restriction Mimetics to Promote the Immune Control of Lung Metastases. Journal of Immunology Research, 2019, 2019, 1-8. | 2.2 | 15 |
| 144 | Mexican Ganoderma Lucidum Extracts Decrease Lipogenesis Modulating Transcriptional Metabolic Networks and Gut Microbiota in C57BL/6 Mice Fed with a High-Cholesterol Diet. Nutrients, 2021, 13, 38. | 4.1 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Antibody-induced activation of p185HER2 in the human lung adenocarcinoma cell line Calu-3 requires bivalency. Cancer Immunology, Immunotherapy, 1993, 36, 397-402. | 4.2 | 14 |
| 146 | ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancerÂpatients undergoing therapy with trastuzumab. Scientific Reports, 2020, 10, 3016. | 3.3 | 14 |
| 147 | MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab. Oncotarget, 2018, 9, 27920-27928. | 1.8 | 14 |
| 148 | Immunocytochemical identification of breast carcinoma cells in effusions using a monoclonal antibody.. Journal of Clinical Pathology, 1982, 35, 1037-1037. | 2.0 | 13 |
| 149 | Molecular cytogenetic characterization of stem-like cancer cells isolated from established cell lines. Cancer Letters, 2010, 296, 206-215. | 7.2 | 13 |
| 150 | Maspin influences response to doxorubicin by changing the tumor microenvironment organization. International Journal of Cancer, 2014, 134, 2789-2797. | 5.1 | 13 |
| 151 | Fhit Nuclear Import Following EGF Stimulation Sustains Proliferation of Breast Cancer Cells. Journal of Cellular Physiology, 2015, 230, 2661-2670. | 4.1 | 13 |
| 152 | Combined targeting of EGFR and HER2 against prostate cancer stem cells. Cancer Biology and Therapy, 2020, 21, 463-475. | 3.4 | 13 |
| 153 | Human Renal Antigen Defined by a Murine Monoclonal Antibody2. Journal of the National Cancer Institute, 1984, 73, 363-369. | 6.3 | 12 |
| 154 | MiR-302b as a Combinatorial Therapeutic Approach to Improve Cisplatin Chemotherapy Efficacy in Human Triple-Negative Breast Cancer. Cancers, 2020, 12, 2261. | 3.7 | 12 |
| 155 | Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis. Molecular Cancer, 2014, 13, 23. | 19.2 | 11 |
| 156 | MicroRNA co-expression patterns unravel the relevance of extra cellular matrix and immunity in breast cancer. Breast, 2018, 39, 46-52. | 2.2 | 11 |
| 157 | Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment. Cellular Oncology (Dordrecht), 2019, 42, 815-828. | 4.4 | 11 |
| 158 | The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. European Journal of Cancer, 2019, 118, 1-9. | 2.8 | 11 |
| 159 | Rapid, Cost-Effective Peptide/Nucleic Acid-Based Platform for Therapeutic Antibody Monitoring in Clinical Samples. ACS Sensors, 2020, 5, 3109-3115. | 7.8 | 11 |
| 160 | Letter to the editor. Breast Cancer Research and Treatment, 2001, 70, 155-156. | 2.5 | 10 |
| 161 | Antibodyâ€mediated blockade of JMJD6 interaction with collagen I exerts antifibrotic and antimetastatic activities. FASEB Journal, 2017, 31, 5356-5370. | 0.5 | 10 |
| 162 | Correspondence. European Journal of Cancer, 1998, 34, 1982-1983. | 2.8 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer. Cellular Oncology (Dordrecht), 2022, 45, 257-274. | 4.4 | 9 |
| 164 | Apoptosis Induction by Trastuzumab: Possible Role of the Core Biopsy Intervention. Journal of Clinical Oncology, 2005, 23, 7238-7240. | 1.6 | 8 |
| 165 | Linking survival of HER2-positive breast carcinoma patients with surgical invasiveness. European Journal of Cancer, 2006, 42, 1057-1061. | 2.8 | 8 |
| 166 | Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. Clinical Cancer Research, 2021, 27, 6307-6313. | 7.0 | 8 |
| 167 | The HER2 World: Better Treatment Selection for Better Outcome. Journal of the National Cancer Institute Monographs, 2011, 2011, 82-85. | 2.1 | 7 |
| 168 | Influence of fatty acidâ€free diet on mammary tumor development and growth rate in HERâ€2/neu transgenic mice. Journal of Cellular Physiology, 2013, 228, 242-249. | 4.1 | 7 |
| 169 | Identification of Relevant Conformational Epitopes on the HER2 Oncoprotein by Using Large Fragment Phage Display (LFPD). PLoS ONE, 2013, 8, e58358. | 2.5 | 7 |
| 170 | The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine. Frontiers in Oncology, 0, 12, . | 2.8 | 7 |
| 171 | Relevance of Antibody Valency in EGF Receptor Modulation. Scandinavian Journal of Immunology, 1994, 39, 453-458. | 2.7 | 6 |
| 172 | Promise and failure of targeted therapy in breast cancer. Frontiers in Bioscience - Scholar, 2012, S4, 356-374. | 2.1 | 6 |
| 173 | Infrared Spectroscopic Imaging Visualizes a Prognostic Extracellular Matrix-Related Signature in Breast Cancer. Scientific Reports, 2020, 10, 5442. | 3.3 | 6 |
| 174 | A combination of extracellular matrixâ€and interferonâ€associated signatures identifies highâ€grade breast cancers with poor prognosis. Molecular Oncology, 2021, 15, 1345-1357. | 4.6 | 6 |
| 175 | Circulating miRNAs as Novel Non-Invasive Biomarkers to Aid the Early Diagnosis of Suspicious Breast Lesions for Which Biopsy Is Recommended. Cancers, 2021, 13, 4028. | 3.7 | 6 |
| 176 | What if the future of HER2â€positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study. Cancer Medicine, 2022, 11, 332-339. | 2.8 | 6 |
| 177 | Matured human monocyte-derived dendritic cells (MoDCs) induce expansion of CD4+CD25+FOXP3+ T cells lacking regulatory properties. Immunology Letters, 2008, 117, 106-113. | 2.5 | 5 |
| 178 | Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34+ cells in a xenograft model. Breast Cancer Research and Treatment, 2012, 136, 457-467. | 2.5 | 5 |
| 179 | Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain. Cancers, 2021, 13, 4081. | 3.7 | 5 |
| 180 | Alteration of Laminin Production in Small-Cell Lung Carcinoma: Possible Correlation with the Absence of the Basement Membrane. Tumor Biology, 1993, 14, 279-287. | 1.8 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | HER2 and proliferation of wound-induced breast carcinoma. Lancet, The, 2003, 362, 1503. | 13.7 | 4 |
| 182 | HER2 and proliferation of wound-induced breast carcinoma. Lancet, The, 2003, 362, 1503. | 13.7 | 4 |
| 183 | Modulation of DNA repair genes induced by TLR9 agonists. OncoImmunology, 2012, 1, 258-259. | 4.6 | 4 |
| 184 | Prognostic role of tumor size in T1 HER2-positive breast cancers treated with adjuvant trastuzumab. Annals of Oncology, 2014, 25, 1073-1074. | 1.2 | 4 |
| 185 | Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment. Cells, 2020, 9, 434. | 4.1 | 4 |
| 186 | Aerosol 1,25-dihydroxyvitamin D3 supplementation: A strategy to boost anti-tumor innate immune activity. PLoS ONE, 2021, 16, e0248789. | 2.5 | 4 |
| 187 | MOv18 Monoclonal Antibody in Diagnostic Applications: Capability to Recognize the Histotype of the Original Tumor. Tumori, 1990, 76, 10-13. | 1.1 | 3 |
| 188 | Influence of Lignans Depletion on Murine Mammary Gland Morphology. Nutrition and Cancer, 2010, 62, 237-242. | 2.0 | 3 |
| 189 | HER2 splice variants and their relevance in breast cancer. Journal of Nucleic Acids Investigation, 2011, 2, 9. | 0.8 | 3 |
| 190 | The TRAR gene classifier to predict response to neoadjuvant therapy in HER2â€positive and ERâ€positive breast cancer patients: an explorative analysis from the NeoSphere trial. Molecular Oncology, 2022, 16, 2355-2366. | 4.6 | 3 |
| 191 | Folate in Head and Neck Squamous Cell Cancer Chemoprevention: Purposely Left Out?. Journal of Clinical Oncology, 2008, 26, 3463-3463. | 1.6 | 2 |
| 192 | Promise and failure of targeted therapy in breast cancer. Frontiers in Bioscience - Scholar, 2012, S4, 356. | 2.1 | 2 |
| 193 | microRNA: New Players in Metastatic Process. , 2013, , . | | 2 |
| 194 | Biomimicking of the Breast Tumor Microenvironment. Current Molecular Biology Reports, 2015, 1, 71-76. | 1.6 | 2 |
| 195 | Deep Into Breast Cancer Heterogeneity to Increase Immunotherapeutic Effectiveness. JCO Precision Oncology, 2020, 4, 1267-1268. | 3.0 | 2 |
| 196 | Current and Future Developments in Cancer Therapy Research: miRNAs as New Promising Targets or Tools. , 2012, , 517-546. | | 2 |
| 197 | Worldwide SARS-CoV-2 haplotype distribution in early pandemic. PLoS ONE, 2022, 17, e0263705. | 2.5 | 2 |
| 198 | PET Prediction of Response to Trastuzumab in ErbB2-Positive Human Xenograft Model. Journal of Nuclear Medicine, 2012, 53, 1654-1655. | 5.0 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Ã¢â‚¬Å“OmicsÃ¢â‚¬Â•and Immunologic Approaches to Optimizing Cure Rates in HER2-Positive Breast Carcinomas. Frontiers in Oncology, 2014, 4, 334. | 2.8 | 1 |
| 200 | Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: Results and clinical implications after eight-years follow-up. Breast, 2014, 23, 334-340. | 2.2 | 1 |
| 201 | P53 and microRNAs in chronic lymphocytic leukemia. Journal of Nucleic Acids Investigation, 2011, 2, 8. | 0.8 | 1 |
| 202 | Stromal Responses among Carcinomasâ€”Letter. Clinical Cancer Research, 2014, 20, 1396-1396. | 7.0 | 0 |
| 203 | Non-Human Determinants of Lung Cancer Outcome: A Target for Inhibition of Pro-Metastatic Effect of Surgery, Triggered by Postoperative Bacterial Pneumonia. Journal of Thoracic Oncology, 2019, 14, 2039-2041. | 1.1 | 0 |
| 204 | The 67 kDa laminin receptor as a prognostic factor in human cancer. , 1998, , 227-235. | | 0 |
| 205 | Monoclonal antibodies in oncology. Research in Clinic and Laboratory, 1984, 14, 297-301. | 0.3 | 0 |